Posted by Michael Wonder on 18 Sep 2017
NICE rejects first-line use of Roche’s Gazyvaro
18 September 2017 - The National Institute for Health and Care Excellence has turned down first-line use of Roche’s Gazyvaro in patients with untreated advanced follicular lymphoma on the NHS in England and Wales.
In an appraisal consultation determination, the cost watchdog said Gazyvaro (obinutuzumab) is not recommended, within its anticipated marketing authorisation - first as induction treatment with chemotherapy, then alone as maintenance therapy - for untreated advanced follicular lymphoma in adults.
Current first-line treatment for symptomatic advanced follicular lymphoma is induction therapy with rituximab (Roche’s MabThera is the branded form) plus chemotherapy, followed by maintenance treatment with rituximab when there has been a response.
